Abstract:

Objective To study  the   inhibitory effect of celecoxib on proliferation of    adiramycin(ADM)-resistant  breast cancer cells MCF-7/ADM  and to discuss the anti-tumor effect of  celecoxib.Methods The MCF-7/ADM cells treated with different concentrations of ADM (0.05,0.10,0.20,0.40,0.80,1.60  mg/L) were used as  control groups;the MCF-7/ADM cells treated with cell-free complete medium were used as negative control group and   the cells treated with ADM and  10,20  μmol?L-1  celecoxib were  used as experiment group.The inhibitory rates of cells in various groups were detected by CCK-8 after 24,48 and 72 h.The MCF-7/ADM cells treated with  0.05  mg?L-1 ADM and  different concentrations of celecoxib (10 and 20  μmol/L) were collected 3 h  after treatment,the concentrations of ADM were detected by flow cytometry in various groups.Results The growth of cells were inhibited  24,48 and 72 h after treated  with different concentrations of ADM alone or combined with celecoxib (10 and 20  μmol/L). The inhibitory rates of cells in experiment group were higher than those in contronl group(P<0.05);the inhibitory rates in 20  μmol/Lcelecoxib experiment group were higher than those in 10  μmol/L celecoxib experiment group at  24,48 and 72 h （P<0.05）.The cells in control groups changed little but the cells in experiment group changed a lot,which showed a celecoxib dose-dependent manner.Compared with control groups,the concentrations of ADM in the cells  in experiment group were increased(P<0.05).The concentration of ADM in the cells in 20 μmol/L celecoxib experiment was higher than that in 10 μmol/L celecoxib eperiment group(P<0.05).Conclusion The selective COX-2 inhibitor celecoxib combined with ADM can reverse the ADM resistance  of   breast cancer cell lines.

Key words: celecoxib； breast neoplasm；breast cancer cells； MCF-7/ADM；adiramycin